BioStock: BioInvent receives EMA support for BI-1808
BioInvent has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) regarding orphan drug designation for BI-1808 in cutaneous T-cell lymphoma. According to CEO Martin Welschof, this step – together with the encouraging clinical data generated to date – reinforces the company’s commitment to advancing BI-1808 as a novel immunotherapy for CTCL patients.
Read the article at biostock.se:
BioInvent receives EMA support for BI-1808
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/